Why Medtronic Stock May Have Just Become the Best Buy in the Entire Healthcare Sector

Medtronic reported its strongest growth in 10 years with 8.4% sales increase in fiscal 2026. The medical device maker offers an attractive investment combination: a 3.5% dividend yield (49-year streak of increases), low forward P/E multiple of 14, and diversified operations across 70 health conditions in 150+ countries. Despite being down 15% year-to-date, analysts view it as a compelling long-term buy in the healthcare sector.